{
    "relation": [
        [
            "Citing Patent",
            "US7084121 *",
            "US7642323",
            "US7786133",
            "US8034825",
            "US8067431",
            "US8329958",
            "US8349307",
            "US8389759",
            "US8568705",
            "US8604159",
            "US8901246",
            "US8940801",
            "US9040723",
            "US20040180831 *",
            "US20050054816 *"
        ],
        [
            "Filing date",
            "Mar 23, 2004",
            "Dec 17, 2004",
            "",
            "",
            "Feb 22, 2010",
            "Jul 5, 2005",
            "Oct 6, 2009",
            "Mar 12, 2008",
            "Jul 18, 2006",
            "Jul 22, 2004",
            "Oct 10, 2013",
            "Nov 17, 2009",
            "Aug 28, 2008",
            "Mar 23, 2004",
            "Jul 22, 2004"
        ],
        [
            "Publication date",
            "Aug 1, 2006",
            "Jan 5, 2010",
            "Aug 31, 2010",
            "Oct 11, 2011",
            "Nov 29, 2011",
            "Dec 11, 2012",
            "Jan 8, 2013",
            "Mar 5, 2013",
            "Oct 29, 2013",
            "Dec 10, 2013",
            "Dec 2, 2014",
            "Jan 27, 2015",
            "May 26, 2015",
            "Sep 16, 2004",
            "Mar 10, 2005"
        ],
        [
            "Applicant",
            "Nobex Corporation",
            "Nektar Therapeutics",
            "Nektar Therapeutics",
            "Nektar Therapeutics",
            "Nektar Therapeutics",
            "Biocon Limited",
            "Nektar Therapeutics",
            "Nektar Therapeutics",
            "Nektar Therapeutics",
            "Nektar Therapeutics",
            "Nektar Therapeutics",
            "Nektar Therapeutics",
            "Biocon Limited",
            "Ekwuribe Nnochiri N.",
            "Mcmanus Samuel P."
        ],
        [
            "Title",
            "Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same",
            "Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation",
            "Chemically modified small molecules",
            "Chemically modified small molecules",
            "Chemically modified small molecules",
            "Combinatorial synthesis of PEG oligomer libraries",
            "Polymer conjugates of opioid antagonists",
            "Oligomer-anticholinergic agent conjugates",
            "Method for preparing branched functionalized polymers using branched polyol cores",
            "Method for preparing functionalized polymers from polymer alcohols",
            "Method for preparing branched functionalized polymers using branched polyol cores",
            "Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation",
            "Method of synthesizing a substantially monodispersed mixture of oligomers",
            "Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same",
            "Method for preparing functionalized polymers from polymer alcohols"
        ]
    ],
    "pageTitle": "Patent US6835802 - Methods of synthesizing substantially monodispersed mixtures of polymers ... - Google Patents",
    "title": "",
    "url": "http://www.google.com/patents/US6835802?dq=6859936",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 7,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438043062635.98/warc/CC-MAIN-20150728002422-00112-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 476818627,
    "recordOffset": 476769531,
    "tableOrientation": "HORIZONTAL",
    "TableContextTimeStampAfterTable": "{71378=The molar ratio of the compound capable of ionizing a hydroxyl moiety on the PEG moiety of the compound of Formula IV to the compound of Formula IV is preferably at least about 1:1, and is more preferably at least about 2:1. By providing an excess of the compound capable of ionizing the hydroxyl moiety, it is assured that substantially all of the compounds of Formula IV are reacted to provide the compounds of Formula I. Thus, separation difficulties, which may occur if both compounds of Formula IV and compounds of Formula I were present in the reaction product mixture, may be avoided., 69061=The molar ratio of the compound of Formula I to the compound of Formula II is preferably greater than about 1:1. More preferably, the molar ratio is at least about 2:1. By providing an excess of the compounds of Formula I, one can ensure that substantially all of the compounds of Formula II are reacted, which may aid in the recovery of the compounds of Formula III as discussed below., 74729=The molar ratio of the methane sulfonyl halide to the compound of Formula V is preferably greater than about 1:1, and is more preferably at least about 2:1. By providing an excess of the methane sulfonyl halide, it is assured that substantially all of the compounds of Formula V are reacted to provide the compounds of Formula II. Thus, separation difficulties, which may occur if both compounds of Formula V and compounds of Formula II were present in the reaction product mixture, may be avoided.}",
    "textBeforeTable": "Patent Citations In the specification, there has been disclosed typical preferred embodiments of the invention and, although specific terms are employed, they are used in a generic and descriptive sense only and not for purposes of limitation, the scope of the invention being set forth in the following claims. Oil; Rf 0.41 (methanol:chloroform=6:10); MS m/z calc'd for C25H52O13 560.67 (M++1), found 560.67. 3,6,9,12,15,18,21,24,27,30,33,36-Dodecaoxaheptatricosanol (XXXIV) (m=5) Example 18 Oil; Rf 0.41 (methanol:chloroform=6:10); MS m/z calc'd for C23H48O12 516.31 (M++1), found 516.31. 3,6,9,12,15,18,21,24,27,30,33-Undecaoxatetratriacontanol (XXXIV) (m=4) Example 17 Oil; Rf 0.41 (methanol:chloroform=6:10); MS m/z calc'd for C21H44O11 472.29 (M++1), found 472.29. 3,6,9,12,15,18,21,24,27,30-Decaoxabenetriacontanol (XXXIV) (m=3) Example 16 The non-polydispersed compounds XXXIV were prepared from a diol by using the procedure described above for compound XXXII. Ethylene glycol mono methyl ether (XXXIV) (m=3,4,5) Example 15 Non-polydispersed compound XXXIII was obtained in quantitative yield from the alcohol XXXII (m=4) and methanesulfonyl chloride as described for XXXI, as an oil; Rf 0.4 (ethyl acetate:acetonitrile=1:5); MS m/z calc'd for C17H37O10 433.21 (M++1), found 433.469. 20-methoxy-1-(methylsulfonyl)oxy-3,6,9,12,15,18-hexaoxaeicosane (XXXIII) Example 14 Oil; Rf 0.42 (methanol:chloroform=6:10); MS m/z calc'd for C19H40O10 428.26 (M++1), found 429.3. 3,6,9,12,15,18,21,24,27-Nonaoxaoctacosanol (XXXII) (m=5) Example 13 Oil; Rf 0.43 (methanol:chloroform=6:10); MS m/z calc'd for C17H36O9 384.24 (M++1), found 385.3. 3,6,9,12,15,18,21,24-Octaoxapentacosanol (XXXII) (m=5) Example 12 Oil; Rf 0.46 (methanol:chloroform=3:22);",
    "textAfterTable": "US4348387 Jul 31, 1979 Sep 7, 1982 The Rockefeller University Method and system for the controlled release of biologically active substances to a body fluid US4410547 Aug 6, 1981 Oct 18, 1983 Kabushiki Kaisha Vend Seiyako Oyo Kenkyujo Sorbic acid-containing powder or granules US4469681 Jun 29, 1981 Sep 4, 1984 The Rockefeller University Method and system for the controlled release of biologically active substances to a body fluid US4472382 Feb 23, 1983 Sep 18, 1984 Roussel Uclaf Treatment method US4554101 Jan 28, 1983 Nov 19, 1985 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity US4579730 May 9, 1984 Apr 1, 1986 Hadassah Medical Organization Pharmaceutical compositions containing insulin US4585754 Dec 6, 1984 Apr 29, 1986 Valcor Scientific, Ltd. Stabilization of proteins and peptides by chemical binding with chondroitin US4622392 Jun 21, 1984 Nov 11, 1986 Health Research Inc. (Roswell",
    "hasKeyColumn": false,
    "keyColumnIndex": -1,
    "headerRowIndex": 0
}